Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zidovudine and Didanosine Regimens in Early HIV-1
NCT00000823Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zidovudine and didanosine in human immunodeficiency virus type 1 infection (HIV-1) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Quantitative Measures of Viral Burden. Status: completed.
02
Drugs
zidovudinedidanosine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00000823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000823.